AstraZeneca published two separate Phase III topline results on August 17, 2026, both in non-small cell lung cancer (NSCLC), both hitting their primary endpoints, and both reinforcing the company’s position across two of its biggest lung cancer franchises at once. One release covers Enhertu in HER2-mutant NSCLC, the other covers Tagrisso plus Orpathys in EGFR-mutant, MET-driven resistant NSCLC. The drugs, patient populations, and endpoints are distinct enough that they shouldn’t be conflated, so each trial is broken out separately below, but the shared timing is itself the story: AstraZeneca used a single day to advance two different lung cancer treatment strategies simultaneously.
DESTINY-Lung04: Enhertu Moves Toward First-Line HER2-Mutant Lung Cancer
The DESTINY-Lung04 trial, run jointly with Daiichi Sankyo, tested Enhertu (trastuzumab deruxtecan) against the current standard of care, chemotherapy plus pembrolizumab, as a first-line treatment for unresectable, locally advanced or metastatic HER2-mutant non-squamous NSCLC. The global, randomized, open-label study enrolled 454 patients across Asia, Europe, and North America, and AstraZeneca reports it hit its primary endpoint of progression-free survival with a statistically significant and clinically meaningful improvement. Enhertu is already approved as a second-line treatment for HER2-mutant metastatic NSCLC; this trial is testing whether it can move earlier, into the first-line setting. Susan Galbraith, AstraZeneca’s Executive Vice President of Oncology Haematology R&D, framed the result as a first for the field: “DESTINY-Lung04 becoming the first Phase III trial to demonstrate a progression-free survival benefit versus the global standard of care in this first-line setting, supporting the potential for Enhertu to move earlier in the treatment of HER2-mutant non-small cell lung cancer. This aggressive lung cancer often affects younger patients and has historically had limited first-line targeted treatment options, making these positive results an important step forward in bringing additional effective therapies to patients at metastatic diagnosis when there is the greatest opportunity to improve outcomes.” Daiichi Sankyo’s Global Head of R&D, John Tsai, added: “Enhertu is already established as the first and only antibody drug conjugate for the second-line treatment of HER2-mutant metastatic non-small cell lung cancer. The positive results seen in DESTINY-Lung04 show that treatment with Enhertu in the first-line setting delays disease progression compared to the global standard of care.” HER2 mutations show up in roughly 2 to 4% of NSCLC cases, a relatively narrow slice of lung cancer overall, but one with historically limited first-line targeted options.
SAFFRON: Tagrisso Plus Orpathys Tackles a Known Resistance Pathway
The second trial, SAFFRON, addresses a different problem entirely: what happens after Tagrisso (osimertinib) stops working. Roughly one in three patients on third-generation EGFR-TKIs like Tagrisso eventually develop MET overexpression or amplification, one of the most common resistance mechanisms that lets tumors escape treatment, a development the release describes as associated with poor prognosis and a significant unmet need in later-line settings. SAFFRON tested adding Orpathys (savolitinib), a MET inhibitor developed with HUTCHMED, to ongoing Tagrisso treatment against platinum-based chemotherapy in 338 patients across 230 centers in 29 countries, all of whom had EGFR-mutated NSCLC with MET overexpression or amplification that had progressed after first- or second-line Tagrisso. The trial hit both its primary endpoint of progression-free survival and the key secondary endpoint of overall survival with statistically significant, clinically meaningful improvements. Galbraith described the strategic logic behind combining the two drugs rather than switching therapies entirely: “These data demonstrate the clear benefit of adding Orpathys to backbone therapy Tagrisso to address MET overexpression or amplification while maintaining EGFR suppression. By combining Orpathys and Tagrisso, with its established efficacy, safety profile and central nervous system protection, we aim to deliver the first biomarker-directed, all-oral option in this setting to patients across the globe. This further strengthens our leadership in EGFR-mutated lung cancer.” HUTCHMED CEO Weiguo Su tied the global trial back to earlier regional data: “The SAFFRON global study further reinforces the robust efficacy previously demonstrated in the SACHI Phase III trial that supported approval in China, with the results providing clear evidence to support global registrations of the Tagrisso and Orpathys combination.” Tagrisso has already been used to treat more than a million patients worldwide across its existing indications, making this less a launch of something new and more a defense of already-dominant market territory against a well-understood resistance pathway.
What’s Actually Been Disclosed So Far
Both releases are topline results only. Neither includes hazard ratios, median progression-free survival figures, or median overall survival figures, AstraZeneca says the full DESTINY-Lung04 and SAFFRON datasets will be presented at a forthcoming medical meeting and shared with global regulatory authorities. That’s a meaningful caveat: “statistically significant and clinically meaningful improvement” is a real result, but the actual magnitude of benefit, and how it compares against other options in each setting, won’t be clear until the detailed data are presented.
The Bigger Picture
Taken together, the two announcements read as AstraZeneca shoring up its lung cancer franchise from two different angles on the same day: extending Enhertu’s HER2-mutant footprint earlier into the treatment journey, while defending Tagrisso’s EGFR-mutant dominance against the resistance mechanism most likely to eventually undercut it. Lung cancer remains one of AstraZeneca’s most important oncology categories, and pairing a forward-looking expansion with a defensive fortification in the same news cycle is a fairly clear signal of where the company’s oncology R&D priorities currently sit. It also echoes a strategy that’s already paid off elsewhere in the pipeline — Enhertu’s expansion mirrors its earlier success reaching into hormone receptor-positive breast cancer — a good sign for where AstraZeneca’s broader cancer research is headed next.
